23 November 2022
10 November 2022
-Company to host conference call via webcast at 10 am ET -
NEW YORK, November 10, 2022-- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today...Read more
04 November 2022
NEW YORK, November 04, 2022-- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company plans to host an investor call and...Read more
Our mission is to bring breakthrough therapies to patients with the aim of treating SPMS, Crohn's Disease, lung diseases and optimizing health outcomes.Learn more
Our major clinical assets are supported by extensive worldwide issued patents and pending patent applications covering composition of matter, formulation technologies, manufacturing processes and disease indications.
Foralumab is a fully human anti-CD3 monoclonal antibody (mAb) for treatment of Crohn’ s Disease and neurodegenerative indications.Learn more about Foralumab
We are developing a fully human monoclonal antibody (mAb) targeting the receptor for IL-6 as a potential treatment for lung diseases.Learn more about Anti IL-6R
Milciclib is the Company’s clinical candidate for the treatment in cancer indications. The company is exploring the combination of milciclib and gemcitibine in NSCLC patients with pan KRAS+ mutations.Learn more about Milciclib
Tiziana is currently conducting clinical development programs for Foralumab, Anti IL-6R and Milciclib
Tiziana reported positive clinical data in a Phase I clinical trial of nasally-dosed Foralumab in healthy subjects in collaboration with Dr. Howard Weiner at Brigham and Women’s Hospital in Boston. Phase 2 patient enrollment is expected to begin in 1H 2022 for nasally administered Foralumab for the treatment of Non-active SPMS.See more Foralumab clinical trials
Manufacturing of clinical supplies for a Phase 1 study is anticipated to be completed in 4Q 2022.
We are exploring a study to evaluate the combination of milciclib and gemcitabine in NSCLC subjects with associated pan KRAS-positive mutations.See more Milciclib clinical trials